Acromegaly is usually caused by a noncancerous tumor. Middle-aged adults are most commonly affected. Symptoms include enlargement of the face, hands, and feet. Prompt treatment is needed to avoid serious illness. Drugs can reduce the effects of growth hormone. If needed, surgery and radiation may be used to remove tumor cells.
In an important new development Swiss-based Debiopharm entered a Phase 3 trial of a new Octreotide formulation. The company is currently recruiting patients for the study. Debio 4126 is a sustained-release formulation designed to improve the convenience of somatostatin analogue (SSA) therapy for the treatment of acromegaly.
Could artificial intelligence and machine learning recognize the early, subtle changes in people’s faces associated with the hormonal disease acromegaly? New research spearheaded by Dr. Manel Puig-Domingo and outlined in a recent paper published in the journal PITUITARY raises the possibility that AI algorithms and machine learning could provide a game-changing approach to the early diagnosis of this complex disease, which now takes an average of 6 to 10 years to diagnose.
Crinetics announced today that the FDA has approved PALSONIFY™, the first once-daily oral therapy to treat acromegaly. The company announced the drug will be available in early October.
I recently had the pleasure of meeting Camurus CEO Fredrik Tiberg. We initially connected on a Zoom call and later met at the European Endocrine Conference held in Copenhagen, Denmark in May. We agreed to meet in person, learn more about the company and record a podcast.
From the desk of J D Faccinetti – co Founder and chief editor – Today, I am pleased to share two new excellent resources from Crinetics Phamaceuticals: AcromegalyReality.com – This newly launched site offers support
This captivating conversation offers an intimate look at how endocrine fellows train on pituitary disorders and their confidence in managing these conditions post-fellowship.
This fantastic presentation by Dr. John Carmichael, Distinguished Professor of Clinical Medicine at the University of Southern California and Co-director of the USC Pituitary Center focuses on the controversies arising from the clinical dilemmas present in treating a complicated condition like acromegaly.
SAN FRANCISCO, BARCELONA, TORONTO – October 31, 2024 – Artificial Intelligence (AI) could play a significant role in aiding the diagnosis of rare diseases. This is especially true for facial recognition and machine learning in
From J D Faccinetti, co-founder – It is often said that once you know people with acromegaly, you will see it more often. It makes you wonder how apt the definition of “rare” is for
Explore why renaming pituitary cysts matters in acromegaly care and how better terms can improve diagnosis and treatment.
